Immunome, Inc.
IMNM
$5.56
-$0.32-5.44%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.74M | 2.91M | 2.36M | 1.03M | 3.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.74M | 2.91M | 2.36M | 1.03M | 3.83M |
| Cost of Revenue | 47.89M | 37.20M | 29.08M | 15.37M | 9.64M |
| Gross Profit | -45.15M | -34.29M | -26.72M | -14.34M | -5.81M |
| SG&A Expenses | 10.45M | 9.53M | 6.98M | 6.01M | 8.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.34M | 46.73M | 36.06M | 21.37M | 17.68M |
| Operating Income | -55.60M | -43.82M | -33.70M | -20.35M | -13.85M |
| Income Before Tax | -80.25M | -47.10M | -36.12M | -129.49M | -92.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.25M | -47.10M | -36.12M | -129.49M | -92.63M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.25M | -47.10M | -36.12M | -129.49M | -92.63M |
| EBIT | -55.60M | -43.82M | -33.70M | -20.35M | -13.85M |
| EBITDA | -55.15M | -43.41M | -33.15M | -20.19M | -13.70M |
| EPS Basic | -1.28 | -0.78 | -0.60 | -2.51 | -2.16 |
| Normalized Basic EPS | -0.53 | -0.42 | -0.31 | -0.21 | -0.17 |
| EPS Diluted | -1.28 | -0.78 | -0.60 | -2.51 | -2.16 |
| Normalized Diluted EPS | -0.53 | -0.42 | -0.31 | -0.21 | -0.17 |
| Average Basic Shares Outstanding | 62.84M | 60.21M | 59.94M | 51.54M | 42.79M |
| Average Diluted Shares Outstanding | 62.84M | 60.21M | 59.94M | 51.54M | 42.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
